{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:19Z","timestamp":1707524299874},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,29]]},"DOI":"10.7759\/cureus.16009","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T08:53:50Z","timestamp":1624956830000},"source":"Crossref","is-referenced-by-count":0,"title":["Invasive Fungal Infection Complicating Treatment With Ibrutinib"],"prefix":"10.7759","author":[{"given":"Pramuditha","family":"Rajapakse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rewaida","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714539906","article-title":"Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib","volume":"5","author":"Aalipour A","year":"2014","unstructured":"Aalipour A, Advani RH. Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 2014, 5:121-33. 10.1177\/2040620714539906","journal-title":"Ther Adv Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro RA","year":"2015","unstructured":"de Claro RA, Karen M, Verdun N, et al.. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015, 21:3586-90. 10.1158\/1078-0432.CCR-14-2225","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-019-0376-1","article-title":"The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy","volume":"48","author":"Mascarella MA","year":"2019","unstructured":"Mascarella MA, Schweitzer L, Alreefi M, et al.. The infectious thyroid nodule: a case report of mucormycosis associated with ibrutinib therapy. J Otolaryngol Head Neck Surg. 2019, 48:49. 10.1186\/s40463-019-0376-1","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.4323.4323","article-title":"Ibrutinib: a risk factor for invasive fungal infections?","volume":"130","author":"Ruchlemer R","year":"2017","unstructured":"Ruchlemer R, Ben Ami R, Bar-Meir M, et al.. Ibrutinib: a risk factor for invasive fungal infections?. Blood. 2017, 130:4323. 10.1182\/blood.V130.Suppl_1.4323.4323","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, Outcomes, and Risk Factors of Invasive Fungal Infections in Adult Patients with Acute Myelogenous Leukemia after Induction Chemotherapy.","volume":"75","author":"Neofytos D","year":"2013","unstructured":"Neofytos D, Kit L, Amy H, et al.. Epidemiology, Outcomes, and Risk Factors of Invasive Fungal Infections in Adult Patients with Acute Myelogenous Leukemia after Induction Chemotherapy.. Diagnostic Microbiology and Infectious Disease. 2013, 75:144-49.","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lmphoma","volume":"31","author":"Lionakis MS","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, et al.. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lmphoma. Cancer Cell. 2017, 31:833-43.e5. 10.1016\/j.ccell.2017.04.012","journal-title":"Cancer Cell"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos G","year":"2018","unstructured":"Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis. 2018, 66:140-8. 10.1093\/cid\/cix687","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.05.004","article-title":"Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis","volume":"31","author":"Grommes C","year":"2017","unstructured":"Grommes C, Younes A. Ibrutinib in PCNSL: the curious cases of clinical responses and aspergillosis. Cancer Cell. 2017, 31:731-3. 10.1016\/j.ccell.2017.05.004","journal-title":"Cancer Cell"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations","volume":"31","author":"Pagano L","year":"2017","unstructured":"Pagano L, Busca A, Candoni A, et al.. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev. 2017, 31:17-29. 10.1016\/j.blre.2016.09.002","journal-title":"Blood Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.1.4.349","article-title":"Fungal infections of the immunocompromised host: clinical and laboratory aspects","volume":"1","author":"Musial CE","year":"1988","unstructured":"Musial CE, Cockerill FR 3rd, Roberts GD. Fungal infections of the immunocompromised host: clinical and laboratory aspects. Clin Microbiol Rev. 1988, 1:349-64. 10.1128\/cmr.1.4.349","journal-title":"Clin Microbiol Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer R","year":"2019","unstructured":"Ruchlemer R, Ben-Ami R, Bar-Meir M, et al.. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study. Mycoses. 2019, 62:1140-7. 10.1111\/myc.13001","journal-title":"Mycoses"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving Ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese T","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N, et al.. Serious infections in patients receiving Ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018, 67:687-92. 10.1093\/cid\/ciy175","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis","volume":"58","author":"Baron M","year":"2017","unstructured":"Baron M, Zini JM, Belval TC, et al.. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017, 58:2981-2. 10.1080\/10428194.2017.1320710","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1775215","article-title":"Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"61","author":"Frei M","year":"2020","unstructured":"Frei M, Aitken SL, Jain N, et al.. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leukemia & Lymphoma. 2020, 61:2488-91. 10.1080\/10428194.2020.1775215","journal-title":"Leukemia & Lymphoma"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern","volume":"131","author":"Rogers K","year":"2018","unstructured":"Rogers K. Ibrutinib and fungus: an invasive concern. Blood. 2018, 131:1882-4. 10.1182\/blood-2018-02-832154","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/59215-invasive-fungal-infection-complicating-treatment-with-ibrutinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:20Z","timestamp":1707507080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/59215-invasive-fungal-infection-complicating-treatment-with-ibrutinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.16009","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,29]]}}}